FGIN-1-27 - CAS 142720-24-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C28H37FN2O
Molecular Weight:
436.61
COA:
Inquire
Targets:
GABA Receptor
Description:
FGIN-1-27 is a high affinity agonist of mitochondrial benzodiazepine receptors (PBR) binding to benzodiazepine receptors on mitochondrial membranes. FGIN-1-27 indirectly potentiates GABAA receptor signaling to exhibit anticonvulsant, anxiolytic, and sedative activity in both animal and clinical models.
Brife Description:
PBR agonist
Purity:
≥98% by HPLC
Synonyms:
N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide; 2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide
MSDS:
Inquire
InChIKey:
VUWXAQFLTSBUDB-UHFFFAOYSA-N
InChI:
InChI=1S/C28H37FN2O/c1-3-5-7-11-19-31(20-12-8-6-4-2)27(32)21-25-24-13-9-10-14-26(24)30-28(25)22-15-17-23(29)18-16-22/h9-10,13-18,30H,3-8,11-12,19-21H2,1-2H3
Canonical SMILES:
CCCCCCN(CCCCCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)F
1.Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents.
Ugale RR;Hirani K;Morelli M;Chopde CT Neuropsychopharmacology. 2004 Sep;29(9):1597-609.
Olanzapine increases brain allopregnanolone (ALLO) levels sufficiently to modulate neuronal activity by allosterically regulating GABAA receptors. Recently, we reported the antipsychotic-like profile of ALLO in rodents. The present study examined the hypothesis that olanzapine-induced elevation of endogenous neurosteroid ALLO is vital for its neuroleptic-like action. The conditioned avoidance response (CAR) and apomorphine-induced climbing behavioral paradigms were used in rodents. Administration of ALLO (1 microg, intracerebroventricular (i.c.v.)) or neurosteroidogenic agents such as the mitochondrial diazepam binding inhibitor receptor agonist, FGIN 1-27 (0.5 microg, i.c.v.) or the ALLO precursor, progesterone (10 mg/kg, i.p.) significantly potentiated olanzapine-induced blockade of CAR and apomorphine-induced climbing. In contrast, these agents failed to alter the antipsychotic-like effect of risperidone and haloperidol. On the other hand, inhibition of the endogenous biosynthesis of neurosteroids by the 3beta-hydroxysteroid dehydrogenase inhibitor, trilostane (30 mg/kg, i.p.), the 3alpha-hydroxysteroid oxidoreductase inhibitor, indomethacin (5 mg/kg, i.p.), or the GABAA receptor antagonist bicuculline (1 mg/kg, i.
2.Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis.
Tokuda K;O'Dell KA;Izumi Y;Zorumski CF J Neurosci. 2010 Dec 15;30(50):16788-95. doi: 10.1523/JNEUROSCI.4101-10.2010.
Benzodiazepines (BDZs) enhance GABA(A) receptor inhibition by direct actions on central BDZ receptors (CBRs). Although some BDZs also bind mitochondrial receptors [translocator protein (18 kDa) (TSPO)] and promote the synthesis of GABA-enhancing neurosteroids, the role of neurosteroids in the clinical effects of BDZs is unknown. In rat hippocampal slices, we compared midazolam, an anesthetic BDZ, with clonazepam, an anticonvulsant/anxiolytic BDZ that activates CBRs selectively. Midazolam, but not clonazepam, increased neurosteroid levels in CA1 pyramidal neurons without changing TSPO immunostaining. Midazolam, but not clonazepam, also augmented a form of spike inhibition after stimulation adjacent to the pyramidal cell layer and inhibited induction of long-term potentiation. These effects were prevented by finasteride, an inhibitor of neurosteroid synthesis, or 17PA [17-phenyl-(3α,5α)-androst-16-en-3-ol], a blocker of neurosteroid effects on GABA(A) receptors. Moreover, the synaptic effects were mimicked by a combination of clonazepam with FGIN (2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide), a selective TSPO agonist, or a combination of clonazepam with exogenous allopregnanolone.
3.Characterization of binding sites for the omega3 receptor ligands [3H]PK11195 and [3H]RO5-4864 in human brain.
Rao VL;Butterworth RF Eur J Pharmacol. 1997 Dec 4;340(1):89-99.
The kinetics and pharmacology of the isoquinoline and benzodiazepine binding sites of the omega3 or peripheral-type benzodiazepine receptors were studied using the specific ligands [3H] 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin -2-one ([3H]PK11195) and [3H]1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarb oxamide ([3H]RO5-4864), respectively. Binding of both ligands was saturable, reversible, displayed nanomolar affinity, and best fit to a single site model. Occipital cortex and cerebellum displayed highest and lowest densities of binding sites respectively; for both ligands. Bmax values of [3H]PK11195 were several-fold higher than that of [3H]RO5-4864 in all regions studied consistent with their binding to distinct subunits of the human peripheral-type benzodiazepine receptor heteromeric complex. However, the isoquinoline and benzodiazepine ligands were found to be mutually competitive at nanomolar concentrations suggesting allosteric interactions between these two sites. Competition binding experiments showed that the binding of both ligands was displaced by diazepam with Ki values in the nM range, and by clonazepam in the microM range. The novel peripheral-type benzodiazepine receptor ligand 2-(4-fluorophenyl)-N,N-di-n-hexyl-1H-indole-3-acetamide (FGIN1-27) displaced only [3H]PK11195 binding with high potency.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 117857-45-1 Loreclezole hydrochloride

Loreclezole hydrochloride
(CAS: 117857-45-1)

Loreclezole hydrochloride is a subtype-selective GABAA receptor modulator. It acts as a positive allosteric modulator of β2 or β3-subunit containing receptors.

CAS 207306-50-1 TB 21007

TB 21007
(CAS: 207306-50-1)

TB 21007, as a nootropic drug, is a GABAA receptor inverse agonist selective for the α5-subtype (Ki values are 1.6, 16, 20 and 20 nM for α5, α2, α1 and α3 subty...

CAS 344413-67-8 Lesogaberan

Lesogaberan
(CAS: 344413-67-8)

Lesogaberan is a potent and selective GABAB receptor agonist that limit the clinical use of baclofen for the treatment of GERD.

RuBi GABA trimethylphosphine

RuBi GABA trimethylphosphine is the modified version of RuBi-GABA, which inhibits neural activity in vivo and is suitable for use as alternative for GABA agonis...

CAS 783331-24-8 MRK 016

MRK 016
(CAS: 783331-24-8)

MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator with EC50 value of 3 nM. It has nootropic properties. MRK-016 can produce rapid...

CAS 128201-89-8 N-ArachidonylGABA

N-ArachidonylGABA
(CAS: 128201-89-8)

N-ArachidonylGABA is first isolated from bovine brain. It was also found to inhibit normal responses to pain in vivo, but has not been fully characterized to da...

CAS 840486-93-3 adipiplon

adipiplon
(CAS: 840486-93-3)

Adipiplon is GABAA receptor partial agonist. It can bind to the α3 subtype. Adipiplon is one of the first drugs selected for clinical development which is able ...

CAS 139667-74-6 CGP 52432

CGP 52432
(CAS: 139667-74-6)

CGP52432 is a potent and selective GABAB receptor antagonist with IC50 value of 85 nM.

CAS 71424-95-8 3-Methyl-GABA

3-Methyl-GABA
(CAS: 71424-95-8)

3-Methyl-GABA is an activator of GABA aminotransferase.

CAS 1135210-68-2 Tracazolate hydrochloride

Tracazolate hydrochloride
(CAS: 1135210-68-2)

Tracazolate hydrochloride is a subtype-selective GABAA receptor modulator that potentiates or inhibits recombinant GABAA function depending on subunit combinati...

CAS 951650-22-9 NS 11394

NS 11394
(CAS: 951650-22-9)

NS 11394 is a drug with selectivity for the α3 and α5 subtypes. It acts as a subtype-selective positive allosteric modulator at GABAA receptors. It is used as a...

CAS 371962-01-5 ZAPA sulfate

ZAPA sulfate
(CAS: 371962-01-5)

ZAPA sulfate acts as an agonist at low affinity GABAA receptors and is thus a useful ligand to investigate GABA receptors linked to benzodiazepine receptors. ZA...

CAS 733717-87-8 SCH-50911

SCH-50911
(CAS: 733717-87-8)

CH-50911 is a selective GABA-B antagonist with IC50 value of 1.1 μM. It is developed by Schering-Plough Corporation. CH-50911 is often used in pharmacology rese...

CAS 339-72-0 L-Cycloserine

L-Cycloserine
(CAS: 339-72-0)

L-Cycloserine is excitatory amino acid, an antibiotic effective against Mycobacterium tuberculosis.

CAS 220860-50-4 CP-457920

CP-457920
(CAS: 220860-50-4)

CP-457920, also called as NGD 971, is a selective α5 GABAA receptor inverse agonist (Ki of ~ 1 ng/mL). CP-457920 was progressed into clinical studies for the tr...

CAS 21967-41-9 Baicalin

Baicalin
(CAS: 21967-41-9)

Baicalin is a flavone found in several species in the genus Scutellaria, including Scutellaria baicalensis and Scutellaria lateriflora. Baicalin is a positive a...

CAS 145645-62-1 NNC 711

NNC 711
(CAS: 145645-62-1)

NNC 711 is a GABA uptake inhibitor by GAT-1 with IC50 values of 0.04, 171, 1700 and 622 μM for hGAT-1, rGAT-2, hGAT-3 and hBGT-1. NNC 711 is an anticonvulsantag...

CAS 164025-44-9 PZ-II-029

PZ-II-029
(CAS: 164025-44-9)

PZ-II-029,a pyrazoloquinolinone, was reported as the first postitive modulator of GABAA α6β3γ2 subtype functionally selective ligands to date.

CAS 64603-91-4 Gaboxadol

Gaboxadol
(CAS: 64603-91-4)

Gaboxadol is a GABA agonist. It was a non-opioid analgesic and a novel type of hypnotic. It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-...

CAS 142720-24-9 FGIN-1-27

FGIN-1-27
(CAS: 142720-24-9)

FGIN-1-27 is a high affinity agonist of mitochondrial benzodiazepine receptors (PBR) binding to benzodiazepine receptors on mitochondrial membranes. FGIN-1-27 i...

Chemical Structure

CAS 142720-24-9 FGIN-1-27

Quick Inquiry

Verification code

Featured Items